- Home
- FFA vs CYRX Comparison
FFA vs CYRX Comparison
Compare FFA & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFA | CYRX |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.9M | 419.3M |
| IPO Year | 2004 | 2008 |
Fundamental Metrics
Financial Performance| Metric | FFA | CYRX |
|---|---|---|
| Price | $21.68 | $10.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.94 |
| AVG Volume (30 Days) | 35.8K | ★ 404.5K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | $8.45 |
| P/E Ratio | ★ N/A | $7.11 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.46 | $5.21 |
| 52 Week High | $22.31 | $11.45 |
Technical Indicators
Market Signals| Indicator | FFA | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.62 | 71.38 |
| Support Level | $21.02 | $9.18 |
| Resistance Level | $21.78 | $10.23 |
| Average True Range (ATR) | 0.35 | 0.42 |
| MACD | 0.20 | 0.18 |
| Stochastic Oscillator | 98.25 | 90.10 |
Price Performance
Historical ComparisonAbout FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.